COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION
The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brown adipocytes and white adipocytes. They also protect primary cardiomyocytes against hypertrophy induced by adrenergic agonists. Such compounds and methods are useful in the treatment and prevention of conditions such as obesity and associated complex metabolic, endocrine, and hemodynamic changes, as well as related conditions as dyslipidemias, cardiovascular disease, and type 2 diabetes..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Europäisches Patentamt - (2024) vom: 03. Apr. Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
VERGNES LAURENT [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-04-03, Last update posted on www.tib.eu: 2024-04-16, Last updated: 2024-04-19 |
---|
Patentnummer: |
EP4132914 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA000039225 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA000039225 | ||
003 | DE-627 | ||
005 | 20240419122358.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA000039225 | ||
035 | |a (EPA)EP4132914 | ||
035 | |a (EPA)78023577 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a VERGNES LAURENT |e verfasserin |4 aut | |
245 | 1 | 0 | |a COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2024-04-03, Last update posted on www.tib.eu: 2024-04-16, Last updated: 2024-04-19 | ||
520 | |a The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brown adipocytes and white adipocytes. They also protect primary cardiomyocytes against hypertrophy induced by adrenergic agonists. Such compounds and methods are useful in the treatment and prevention of conditions such as obesity and associated complex metabolic, endocrine, and hemodynamic changes, as well as related conditions as dyslipidemias, cardiovascular disease, and type 2 diabetes. | ||
650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a REUE KAREN |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 03. Apr. |
773 | 1 | 8 | |g year:2024 |g day:03 |g month:04 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/78023577/publication/EP4132914A1?q=EP4132914 |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2024 |b 03 |c 04 |